Expertos Invitados





PUESTA AL DIA DE LA TERAPIA CON CORTICOIDES INTRANASALES

(especial para SIIC © Derechos reservados)
La rinitis alérgica es una enfermedad crónica del tracto respiratorio superior; en la actualidad afecta a entre el 5% y el 40% de la población general en muchos países desarrollados.
Autor:
Duygu Keskin
Columnista Experto de SIIC

Institución:
Memorial Hospital

Artículos publicados por Duygu Keskin
Coautores
Cemal Cingi* Ibrahim Sayin** 
University of Osmangazi, Eskisehir, Turquía*
Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Estambul, Turquía**
Recepción del artículo
22 de Agosto, 2012 		Aprobación
15 de Octubre, 2012
Primera edición
6 de Diciembre, 2012 		Segunda edición, ampliada y corregida
7 de Junio, 2021

PUESTA AL DIA DE LA TERAPIA CON CORTICOIDES INTRANASALES

Resumen
La rinitis alérgica (RA) es una enfermedad crónica del tracto respiratorio superior cuya prevalencia ha aumentado en las últimas décadas; en la actualidad afecta entre el 5% y 40% de la población general en muchos países desarrollados. Aunque no se asocia con morbilidad grave o mortalidad, en un número considerable de enfermos la RA afecta sustancialmente la calidad de vida. El tratamiento eficaz incluye el tratamiento de la RA y de las comorbilidades. Los corticoides intranasales (CIN) se utilizan para el tratamiento de la RA desde principios de la década de 1970. En la actualidad, los CIN se consideran los agentes más eficaces y la terapia de primera línea para aliviar los síntomas de la RA. Diversos estudios han demostrado que los CIN y, en especial, los preparados más nuevos, son fármacos seguros, asociados con efectos adversos graves mínimos o nulos. En este trabajo se realizó una actualización de la terapia con CIN.

Palabras clave
corticoides intranasales, corticoides tópicos, rinitis alérgica, seguridad, eficacia, efectos adversos, mecanismo de acción, farmacología


Artículo completo
(castellano)
Extensión:  +/-8.4 páginas impresas en papel A4
Exclusivo para suscriptores/assinantes

Update on therapy with intranasal corticosteroids

Abstract
Allergic rhinitis (AR) is a chronic upper respiratory disease, which has increased in prevalence over the last few decades and currently affects between 5% and 40% of the general population in many developed countries. Although it is not associated with severe morbidity and mortality, allergic rhinitis has a major effect on the quality of life in a large number of patients. An effective approach requires treatment of AR and its comorbidities. Intranasal corticosteroids (INS) have been used for the treatment of rhinitis since the early 1970s. Intranasal corticosteroids are now considered the most effective and first line therapy for the nasal symptoms of allergic rhinitis. Many studies have shown that INS, particularly the newer preparations are safe medications with minimal to no serious side effects. This report presents an update on intranasal corticoid therapy.

Key words
intranasal corticoids, topical corticosteroids, allergic rhinitis, safety, efficacy, side effect, mechanism of action, pharmacology


Full text
(english)
 para suscriptores/ assinantes
Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página   www.siicsalud.com/des/expertocompleto.php/

Especialidades
Principal: Alergia, Otorrinolaringología
Relacionadas: Administración Hospitalaria, Anatomía Patológica, Atención Primaria, Bioquímica, Diagnóstico por Laboratorio, Educación Médica, Endocrinología y Metabolismo, Epidemiología, Farmacología, Genética Humana, Inmunología, Medicina Familiar, Medicina Farmacéutica, Medicina Interna, Neumonología, Oftalmología, Pediatría, Salud Pública



Comprar este artículo
Extensión: 8.4 páginas impresas en papel A4

file05.gif (1491 bytes) Artículos seleccionados para su compra



Enviar correspondencia a:
Cemal Cingi, Department of Otorhinolaryngology, University of Osmangazi, 26020, Sumer Mah. Kar Sokak 10/3, Eskisehir, Turquía
Bibliografía del artículo
1. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy 63(Suppl. 86):8-160, 2008.
2. Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 99:S773-780, 1997.
3. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 24:758-764, 2004.
4. Cingi C, Topuz B, Songu M, Kara CO, Ural A, Yaz A, Yildirim M, Miman MC, Bal C. Prevalence of allergic rhinitis among the adult population in Turkey. Acta Otolaryngol 130(5):600-606, May 2010.
5. Cingi C, Songu M, Ural A, Annesi-Maesano I, Erdogmus N, Bal C, Kahya V, Koc EA, Cakir BO, Selcuk A, Ozlugedik S, Onal K, Midilli R, Ecevit C, Pinar E, Akoglu E, Okuyucu S, Erkan AN. The score for allergic rhinitis study in Turkey. Am J Rhinol Allergy 25(5):333-337, Sep-Oct 2011.
6. Barnes PJ. Molecular mechanisms of steroid action in asthma. J Allergy Clin Immunol 26(Suppl. 3):18-22, 1996.
7. Reed JC, Abidi AH, Alpers JD, et al. Effect of cyclosporine A and dexamethasone on interleukin-2 receptor gene expression. J Immunol 137:150-154, 1986.
8. Meltzer E. The pharmacological basis for the treatment of perennial allergic rhinitis and non-allergic rhinitis with topical corticosteroids. Allergy 52(36 Suppl.):33-40, 1997.
9. Andersson M, Andersson P, Pipkorn U. Topical glucocorticosteroids and allergen-induced increase in nasal reactivity: relationship between treatment time and inhibitory effect. J Allergy Clin Immunol 82:1019-1026, 1988.
10. Mygind N, Andersson M. Topical glucocorticosteroids in rhinitis. Acta Otolaryngol 126:1022-1029, 2006.
11. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 63:1292-1300, 2008.
12. Chervinsky P, Kunjibettu S, Miller DL, Prenner BM, Raphael G, Hall N, Shah T. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 99(1):69-76, Jul 2007.
13. Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol 104(4):S144-S149, 1999.
14. Meltzer EO. The role of nasal corticosteroids in the treatment of rhinitis. Immunol Allergy Clin North Am 31(3):545-560, Aug 2011.
15. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 48(9):956-960, 1997.
16. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 101:S434-S439, 1998.
17. Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids. Otolaryngol Head Neck Surg 129(6):739-750, Dec 2003.
18. Gehanno P, Desfougeres JL. Fluticasone propionate aqueous nasal spray compared with oral loratadine in patients with seasonal allergic rhinitis. Allergy 52(4):445-450, 1997.
19. Stempel DA, Thomas M. Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus nonsedating antihistamines. Am J Manag Care 4:89-96, 1998.
20. Ratner PH, Howland WC 3rd, Arastu R, et al. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 90:536-542, 2003.
21. Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Ann Allergy Asthma Immunol 79(3):237-245, 1997.
22. Berger W, Kaiser H, Gawchik S, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg 129(1):16-23, 2003.
23. Boner AL. Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children. J Allergy Clin Immunology 108:S32-S39, 2001.
24. Wilson AM, Sims EJ, McFarlane LC, Lipworth BJ. Effects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol 102:598-604, 1998.
25. Wilson AM, McFarlance LC, Lipworth BJ. Effects of repeated once daily dosing of three intranasal corticosteroids on basal and dynamic measure of hypothalamic-pituitary-adrenal axis activity. J Allergy Clin Immunol 101:470-474, 1998.
26. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics 105(2):E23-E29, 2000.
27. Schenkel E, Skoner D, Bronsky E, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 105(2):E22, 2000.
28. Allen DB, Meltzer EO, Lemanske RF Jr, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 23:407-413, 2002.
29. Skoner D, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 90(1):56-62, 2003.
30. Martinati LC, Sette L, Chiocca E, et al. Effect of beclomethasone dipropionate nasal aerosol on serum markers of bone metabolism in children with seasonal allergic rhinitis. Clin Exp Allergy 23(12):986-991, 1993.
31. Derby L, Maier WC. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol 105:912-916, 2000.
32. Ozturk F, Yuceturk AV, Kurt E, et al. Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids. ENT Journal 10:846-848, 850-851, 1998.
33. Zitt M, Kosoglou T, and Hubbell J. Mometasone furoate nasal spray: A review of safety and systemic effects. Drug Saf 30:317-326, 2007.
34. Weinstein S, Qaqundah P, Georges G, and Nayak A. Efficacy and safety of triamcinolone acetonide aqueous nasal spray in children aged 2 to 5 years with perennial allergic rhinitis: A randomized, double-blind, placebo-controlled study with an open-label extension. Ann Allergy Asthma Immunol 102:339-347, 2009.
35. Cervin A, Andersson M. Intranasal steroids and septum perforation-an overlooked complication? A description of the course of events and a discussion of the causes. Rhinology 36(3):128-132, 1998.
36. Benninger MS, Hadley JA, Osguthorpe JD, Marple BF, Leopold DA, Derebery MJ, Hannley M. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg 130(1):5-24, Jan 2004.
37. Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 118:648-654, 1998.
38. Holm AF, Fokkens WJ, Godthelp T, et al. 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study. Clin Otolaryngol 23:69-73, 1998.
39. Berkowitz RB, Roberson S, Zora J, et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc 20:167-172, 1999.
40. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 118:1142-1148, 2006.
41. Gerson I, Green L, Fishken D. Patient preference and sensory comparisons of nasal spray allergy medications. J Sensory Stud 14:491-496, 1999.
42. Cingi C, Songu M. Nasal steroid perspective: knowledge and attitudes. Eur Arch Otorhinolaryngol 267(5):725-730, May 2010.
43. Fokkens W, Lund V, Mullol J, et al. EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. Rhinology 20:1-136, 2007.
44. Joe S, Thambi R, Huang J. A systematic review of the use of intranasal steroids in the treatment of chronic rhinosinusitis. Otolaryngol Head Neck Surg 139(3):340-347, 2008.
 
 
 
 
 
 
 
 
 
 
 
 
Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.
ua31618
Inicio/Home

Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008